Open Nav

Please submit your session questions in advance at


  • Phillip Chan, CytoSorbents

CytoSorbents Corporation (NASDAQ: CTSO) is a critical care immunotherapy company commercializing its CytoSorb blood purification technology in 53 countries worldwide to treat deadly inflammation in life-threatening conditions in the ICU (such as sepsis, trauma, burn injury, liver disease, lung injury, pancreatitis and many others) and cardiac surgery. CytoSorb has garnered more than 51,000 human treatments cumulatively as a "razorblade disposable" that is compatible with existing blood pumps in the hospital, with $19.1M in trailing 12-month sales and healthy 72% blended gross margins. 4 major partners: Fresenius Medical Care, Terumo Cardiovascular, Biocon and Dr. Reddys. $25M+ in U.S. grant funding.

  • Date:Monday, February 11
  • Time:2:00 PM - 2:15 PM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23390
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Review of company's technology commercialization efforts and clinical trial plans.
  • Company
  • Company HQ City:Monmouth Junction
  • Company HQ State:New Jersey
  • Company HQ Country:United States
  • Ticker:CTSO
  • Exchange:NASDAQ
  • Year Founded:2006
  • Main Therapeutic Focus:Medical Devices
  • Lead Product in Development:CytoSorb
  • Development Phase of Primary Product:Phase III
Phillip Chan